BRAF mutations are known to play a significant role in papillary thyroid cancer (PTC), with the BRAF V600E mutation being the most common genetic alteration in this type of cancer, occurring in about 45% of sporadic PTC cases in Western countries and up to 90% in Korea 26. Here, BRAF is linked to thyroid gland papillary carcinoma.